Close Menu

360Dx

The startup wants to serve the 50 percent or so of genetic disease patients who haven't obtained a molecular diagnosis despite extensive testing.

The Seattle-based firm believes its novel collection devices are convenient and safe enough to use at home to draw blood for many types of tests.

In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.